4.6 Article

Introduction of High-sensitivity Troponin Assays: Impact on Myocardial Infarction Incidence and Prognosis

Journal

AMERICAN JOURNAL OF MEDICINE
Volume 125, Issue 12, Pages 1205-+

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2012.07.015

Keywords

Acute myocardial infarction; Biomarker; High-sensitivity troponin; Incidence; Prognosis; Troponin

Funding

  1. Swiss National Science Foundation [PASMP3-136995, PP00B-102853]
  2. Swiss Heart Foundation
  3. Prof Cloetta Foundation
  4. University of Basel
  5. Department of Internal Medicine, University Hospital Basel
  6. Abbott
  7. ALERE
  8. Beckman Coulter
  9. BRAHMS
  10. Buhlmann Nanosphere
  11. Roche
  12. Siemens

Ask authors/readers for more resources

OBJECTIVE: The study objective was to compare the incidence and prognosis of acute myocardial infarction when using high-sensitivity cardiac troponin assays instead of a standard cardiac troponin assay for the diagnosis of acute myocardial infarction. METHODS: In a prospective international multicenter study, we enrolled 1124 consecutive patients presenting with suspected acute myocardial infarction. Final diagnoses were adjudicated by 2 independent cardiologists 2 times using all available clinical information: first using standard cardiac troponin levels and second using high-sensitivity cardiac troponin T levels for adjudication. Patients were followed up for a mean of 19 +/- 9 months. RESULTS: The use of high-sensitivity cardiac troponin T instead of standard cardiac troponin resulted in an increase in the incidence of acute myocardial infarction from 18% to 22% (242 vs 198 patients), a relative increase of 22%. Of the 44 additional acute myocardial infarctions, 35 were type 1 acute myocardial infarctions and 9 were type 2 acute myocardial infarctions. This was accompanied by a reciprocal decrease in the incidence of unstable angina (unstable angina, 11% vs 13%). The most pronounced increase was observed in patients adjudicated with cardiac symptoms of origin other than coronary artery disease with cardiomyocyte damage (83 vs 31 patients, relative increase of 268%). Cumulative 30-month mortality rates were 4.8% in patients without acute myocardial infarction, 16.4% in patients with a small acute myocardial infarction detected only by high-sensitivity cardiac troponin T but not standard cardiac troponin, and 23.9% in patients with a moderate/large acute myocardial infarction according to standard cardiac troponin assays and high-sensitivity cardiac troponin T (P < .001). CONCLUSIONS: The introduction of high-sensitivity cardiac troponin assays leads to only a modest increase in the incidence of acute myocardial infarction. The novel sensitive assays identify an additional high-risk group of patients with increased mortality, therefore appropriately classified with acute myocardial infarction (Advantageous Predictors of Acute Coronary Syndromes Evaluation; NCT00470587). (C) 2012 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2012) 125, 1205-1213

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available